Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) CEO Neil Clark speaks to Thomas Warner from Proactive after releasing the clinical-stage biotechnology company's full year results for 2022.
Clark says that Destiny Pharma is focused on finding a partner for its lead asset, XF-73, a nasal gel that decolonizes patients before surgery to prevent post-surgical infections.
He adds that the asset is now "very well positioned" for a partnering programme.